This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010;28(9):781-2; author reply 782-4, 784-5.

doi: 10.2165/11535700-000000000-00000.

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review

Jonathan M Plumb, Andreas Clemens, Brigitta U Monz

PMID: 20824908
DOI: 10.2165/11535700-000000000-00000

Comment

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review

Jonathan M Plumb et al. Pharmacoeconomics. 2010.

. 2010;28(9):781-2; author reply 782-4, 784-5.

doi: 10.2165/11535700-000000000-00000.

Authors

Jonathan M Plumb, Andreas Clemens, Brigitta U Monz

PMID: 20824908
DOI: 10.2165/11535700-000000000-00000

No abstract available

PubMed Disclaimer

Comment on

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Kapoor A, Chuang W, Radhakrishnan N, Smith KJ, Berlowitz D, Segal JB, Katz JN, Losina E. Kapoor A, et al. Pharmacoeconomics. 2010;28(7):521-38. doi: 10.2165/11535210-000000000-00000. Pharmacoeconomics. 2010. PMID: 20550220 Free PMC article.

Similar articles

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L, Tilson L, Walsh C, Barry M. McCullagh L, et al. Pharmacoeconomics. 2009;27(10):829-46. doi: 10.2165/11313800-000000000-00000. Pharmacoeconomics. 2009. PMID: 19803538
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Stevenson M, et al. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Health Technol Assess. 2009. PMID: 19846028 Review.
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Monreal M, et al. Thromb Haemost. 2013 Nov;110(5):987-94. doi: 10.1160/TH12-12-0919. Epub 2013 Aug 22. Thromb Haemost. 2013. PMID: 23965805 Clinical Trial.
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N. Lereun C, et al. J Med Econ. 2011;14(2):238-44. doi: 10.3111/13696998.2011.564699. Epub 2011 Mar 9. J Med Econ. 2011. PMID: 21385145
Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M, Carroll C, Papaioannou D. Holmes M, et al. Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Health Technol Assess. 2009. PMID: 19804690 Review.

See all similar articles

References

1. N Engl J Med. 2008 Jun 26;358(26):2765-75 - PubMed
1. Expert Opin Pharmacother. 2009 Aug;10(11):1769-81 - PubMed
1. N Engl J Med. 2008 Jun 26;358(26):2776-86 - PubMed
1. Lancet. 2008 Jul 5;372(9632):31-9 - PubMed
1. Lancet. 2007 Sep 15;370(9591):949-56 - PubMed

Publication types

Actions
Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information